Life Sciences

First Wave BioPharma Chooses Pace® Life Sciences as CDMO Partner. BOCA RATON, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today the selection of an enhanced enteric microgranule […]

Research involves microgranule delivery formulations for adrulipase BOCA RATON, Fla., Aug. 31, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that an abstract titled, “Formulation Development of Enterically Protected Spray Dried

Acquisition allows Pace® to provide regulatory and quality consulting services to support clients throughout the drug development process and improve commercial compliance in FDA-regulated environments. Minneapolis, MN, August 18, 2022 – Pace® Life Sciences, LLC, a full-service contract development and manufacturing organization (CDMO) and subsidiary of Pace® Science and Technology Company, announced today that it

Frank Tagliaferri, Ph.D., Vice President of Pharmaceutical Development sat down with BioProcess International to discuss the growth the industry, and the growth of Pace® Life Sciences over the past few years. https://www.youtube.com/watch?v=t_w6Re3vZbU

Frank Tagliaferri, Ph.D., VP of Pharmaceutical Development & GM Biocompare, The Buyer’s Guide for Life Sciences Published an Article: The Changing Landscape of Gene Therapy, written by Frank Tagliaferri, Ph.D., VP of Pharmaceutical Development & GM at Pace® Life Sciences (PLS). Read the full article

Acquisition adds significant experience and expertise in the development of liquid, semi-solid, and oral solid dose products for pre-clinical and clinical use allowing Pace to support a growing number of clients throughout the drug development process. Minneapolis, MN, October 11, 2021 – Pace Analytical Life Sciences®, LLC, a subsidiary of Pace Analytical® Services, LLC, a full-service contract development

The installation and validation of our LabVantage Laboratory Information Management System (LIMS) is complete in our Philadelphia site!   Staff at our Philadelphia site worked together with cross-functional teams in Quality, Operations, IT, CSols, Inc. and LabVantage (vendor) to complete the installation and validation of a highly-functional and GMP compliant LIMS system. Lou Forcellini, site